

B1

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
16 October 2003 (16.10.2003)

PCT

(10) International Publication Number  
WO 03/084971 A1

(51) International Patent Classification: C07F 9/50, 9/6568, 9/6555, 9/6509, 9/6506, 15/00, B01J 31/24, C07B 53/00, C07C 45/00, 231/18, C07M 7/00

(74) Common Representative: DEGUSSA AG; Intellectual Property Management, Patente und Marken, Standort Hanau, Postfach 13 45, 63403 Hanau (DE).

(21) International Application Number: PCT/EP03/02162

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 3 March 2003 (03.03.2003)

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

Declaration under Rule 4.17:  
— of inventorship (Rule 4.17(iv)) for US only

(26) Publication Language: English

Published:  
— with international search report(30) Priority Data:  
102 14 988.7 4 April 2002 (04.04.2002) DE


For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicant (for all designated States except US): DEGUSSA AG [DE/DE]; Bennigsenplatz 1, 40474 Düsseldorf (DE).

(72) Inventors; and  
(75) Inventors/Applicants (for US only): BÖRNER, Armin [DE/DE]; Im Winkel 40, 18055 Rostock (DE). HOLZ, Jens [DE/DE]; Alt-Roggentiner Weg 14, 18196 Kessin (DE). MONSEES, Axel [DE/DE]; Falkstrasse 46, 60487 Frankfurt (DE). RIERMEIER, Thomas [DE/DE]; Moselstrasse 7, 65439 Flörsheim (DE). KADYROV, Renat [RU/DE]; Bechternwaldstrasse 77, 65931 Frankfurt (DE). SCHNEIDER, Carsten, A. [DE/DE]; Solmsstrasse 52, 60486 Frankfurt (DE). DINGERDISSEN, Uwe [DE/DE]; Linneweg 1, 64342 Seelheim-Jugenheim (DE). DRAUZ, Karlheinz [DE/DE]; Zur Marienruhe 13, 63579 Freigericht (DE).

WO 03/084971 A1

(54) Title: BISPHOSPHINES AS BIDENTATE LIGANDS




(I)

(57) Abstract: The present invention relates to ligands of the general formula (I). In addition, a process for the production thereof and the use thereof are demonstrated.

### Bisphosphines as bidentate ligands

The present invention relates to bisphosphines as bidentate ligands, a process for the production thereof and their use. In particular, the invention concerns 5 bisphosphines of the general structure (I).



Enantiomer-enriched chiral ligands are used in asymmetric synthesis or asymmetric catalysis. It is essential here for the electronic and stereochemical properties of the 10 ligand to be optimally adapted to the particular catalysis problem. An important aspect of the success of these families of compounds is attributed to the creation of a particularly asymmetric environment of the metal centre by these ligand systems. To utilise such an environment for 15 an effective transfer of chirality, it is advantageous to control the flexibility of the ligand system as an inherent limitation of the asymmetric induction.


Within the family of phosphorus-containing ligands, cyclic phosphines, particularly the phospholanes, have achieved 20 particular significance. Bidentate, chiral phospholanes are, for example, the DuPhos and BPE ligands used in asymmetric catalysis. Ideally, therefore, a chiral ligand basic skeleton capable of versatile modification is available, which can be varied within broad limits in 25 respect of its steric and electronic properties.

The object of this invention is therefore to provide a ligand skeleton analogous to that of the existing phospholane ligands, but which can additionally be varied and used within broad limits and possesses comparably good

catalytic properties. In particular, the invention is based on the object of providing novel, asymmetric, bidentate and chiral phosphine ligand systems for catalytic purposes, which can be produced simply and with 5 high enantiomeric purity.

These and other problems not otherwise specified but arising from the prior art are solved by a family of chiral bidentate bisphosphine compounds of the general formula (I), the compounds according to the invention 10 having two chiral phosphine radicals bonded together via an unsaturated bridge.


By preparing enantiomer-enriched bidentate organophosphorus ligands of the general formula (I),



15

wherein

$\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ , independently of one another, denote  $(\text{C}_1\text{-C}_8)$ -alkyl,  $(\text{C}_2\text{-C}_8)$ -alkoxyalkyl,  $(\text{C}_6\text{-C}_{18})$ -aryl,  $(\text{C}_7\text{-C}_{19})$ -aralkyl,  $(\text{C}_3\text{-C}_{18})$ -heteroaryl,  $(\text{C}_4\text{-C}_{19})$ -heteroaralkyl, 20  $(\text{C}_1\text{-C}_8)$ -alkyl- $(\text{C}_6\text{-C}_{18})$ -aryl,  $(\text{C}_1\text{-C}_8)$ -alkyl- $(\text{C}_3\text{-C}_{18})$ -heteroaryl,  $(\text{C}_3\text{-C}_8)$ -cycloalkyl,  $(\text{C}_1\text{-C}_8)$ -alkyl- $(\text{C}_3\text{-C}_8)$ -cycloalkyl,  $(\text{C}_3\text{-C}_8)$ -cycloalkyl- $(\text{C}_1\text{-C}_8)$ -alkyl, or  $\text{R}^1$  and  $\text{R}^2$  and/or  $\text{R}^3$  and  $\text{R}^4$  represent a  $(\text{C}_3\text{-C}_5)$ -alkylene bridge mono- or polysubstituted with  $(\text{C}_1\text{-C}_8)$ -alkyl,  $\text{HO}$ - 25  $(\text{C}_1\text{-C}_8)$ -alkyl,  $(\text{C}_1\text{-C}_8)$ -alkoxy,  $(\text{C}_2\text{-C}_8)$ -alkoxyalkyl,  $(\text{C}_6\text{-C}_{18})$ -aryl,  $(\text{C}_7\text{-C}_{19})$ -aralkyl,  $(\text{C}_1\text{-C}_8)$ -alkyl- $(\text{C}_6\text{-C}_{18})$ -aryl,  $(\text{C}_3\text{-C}_8)$ -cycloalkyl,  $(\text{C}_1\text{-C}_8)$ -alkyl- $(\text{C}_3\text{-C}_8)$ -cycloalkyl,  $(\text{C}_3\text{-C}_8)$ -cycloalkyl- $(\text{C}_1\text{-C}_8)$ -alkyl, this optionally being linked to a polymer enlargement, 30 and  $\text{A}$  denotes one of the following structures



wherein


R denotes H, (C<sub>1</sub>-C<sub>8</sub>)-alkyl, (C<sub>6</sub>-C<sub>18</sub>)-aryl, (C<sub>7</sub>-C<sub>19</sub>)-aralkyl,  
(C<sub>1</sub>-C<sub>8</sub>)-alkyl-(C<sub>6</sub>-C<sub>18</sub>)-aryl, (C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl,

5 (C<sub>1</sub>-C<sub>8</sub>)-alkyl-(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl,  
(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl-(C<sub>1</sub>-C<sub>8</sub>)-alkyl, or the link to a polymer  
enlargement,

Q = O, NH, NR, previously unknown compounds are obtained,  
which can be successfully used in asymmetric catalysis for

10 the production of organic compounds. Thus, with the  
ligands provided by the invention, complexes or catalysts  
can be produced for the successful hydrogenation of  
mixtures of acylated E- and Z-β-aminoacrylic acids or  
derivatives thereof, among other things. To date, only a  
15 few complexes have been successfully tested for mixtures  
of this family of compounds, and so up to now it has been  
necessary to perform an often complicated purification of  
the E/Z mixtures before hydrogenation, so as to be able to  
react the acylated E-β-aminoacrylic acids and derivates,  
20 which can only be hydrogenated with high enantiomeric  
excesses, separately from Z-components.

The ligands according to the invention preferably  
correspond to structures of the general formula (II),



wherein

A takes on the meaning given above,

R<sup>5</sup> to R<sup>12</sup>, independently of one another, denote

(C<sub>1</sub>-C<sub>8</sub>)-alkyl, HO-(C<sub>1</sub>-C<sub>8</sub>)-alkyl, (C<sub>1</sub>-C<sub>8</sub>)-alkoxy,  
(C<sub>2</sub>-C<sub>8</sub>)-alkoxyalkyl, (C<sub>6</sub>-C<sub>18</sub>)-aryl, (C<sub>7</sub>-C<sub>19</sub>)-aralkyl,  
(C<sub>1</sub>-C<sub>8</sub>)-alkyl-(C<sub>6</sub>-C<sub>18</sub>)-aryl, (C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl,  
(C<sub>1</sub>-C<sub>8</sub>)-alkyl-(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl,

5 (C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl-(C<sub>1</sub>-C<sub>8</sub>)-alkyl,  
or the link to a polymer enlargement.

The ligand systems according to the invention can therefore be attached to a polymer enlargement. The ligands or the complexes/catalysts that can be produced  
10 from them can thus be separated very readily from the low molecular-weight compounds, e.g. by filtration, owing to the link to the polymer enlargement, and are thus accessible to the recycling desired by the invention, which is extremely simple but nonetheless advantageous.  
15 The ligands/complexes can be enlarged in molecular weight by linking to a polymer enlargement, and optionally heterogenised in this way. The enantioselective hydrogenation with complexes or catalysts that have been thus enlarged in molecular weight can therefore proceed in  
20 both a homogeneous and a heterogeneous phase.

**Polymer enlargement:**

The polymer enlargement can be freely selected within the framework of the invention. It is limited on the one hand by considerations of practicability and costs, and on the  
25 other hand by prevailing technical conditions (retention capacity, solubility etc.). Some polymer enlargements for catalysts are known from the prior art (Reetz et al., Angew. Chem. 1997, 109, 1559f.; Seebach et al., Helv. Chim. Acta 1996, 79, 1710f.; Kragl et al., Angew. Chem. 1996,  
30 108, 684f.; Schurig et al., Chem. Ber./Recueil 1997, 130, 879f.; Bolm et al., Angew. Chem. 1997, 109, 773f.; Bolm et al. Eur. J. Org. Chem. 1998, 21f.; Baystone et al. in Speciality Chemicals 224f.; Salvadori et al., Tetrahedron: Asymmetry 1998, 9, 1479; Wandrey et al., Tetrahedron:  
35 Asymmetry 1997, 8, 1529f.; ibid. 1997, 8, 1975f.; Togni et

al. J. Am. Chem. Soc. 1998, 120, 10274f., Salvadori et al., Tetrahedron Lett. 1996, 37, 3375f; WO 98/22415; particularly DE 19910691.6; Janda et al., J. Am. Chem. Soc. 1998, 120, 9481f.; Andersson et al., Chem. Commun. 1996, 1135f.; Janda et al., Soluble Polymers 1999, 1, 1; Janda et al., Chem. Rev. 1997, 97, 489; Geckler et al., Adv. Polym. Sci. 1995, 121, 31; White et al., in "The Chemistry of Organic Silicon Compounds" Wiley, Chichester, 1989, 1289; Schuberth et al., Macromol. Rapid Commun. 1998, 19, 309; Sharma et al., Synthesis 1997, 1217; "Functional Polymers" Ed.: R. Arshady, ASC, Washington, 1996; "Praktikum der Makromolekularen Stoffe", D. Braun et al., VCH-Wiley, Weinheim 1999).

It is also preferred for the polymer enlargement to be formed by polyacrylates, polyacrylamides, polyvinylpyrrolidinones, polysiloxanes, polybutadienes, polyisoprenes, polyalkanes, polystyrenes, polyoxazolines or polyethers, or mixtures thereof. In an especially preferred embodiment, polystyrenes are used to construct the polymer enlargement.

Linkers:

Between the actual ligand and the polymer enlargement, a linker can be incorporated. The linker serves to create a distance between ligand and polymer to reduce or eliminate mutual interactions that are disadvantageous to the reaction.

The linkers can, in principle, be freely selected by the person skilled in the art. They should be selected according to the aspects of how well they can be coupled to the polymer/monomer on the one hand and to the ligand on the other hand. Suitable linkers can be found e.g. in the literature references mentioned above under the heading of "Polymer enlargement".

Within the framework of the invention, these active units of formulae (I) to (IV) are therefore advantageously bound

to the polymer enlargement directly, or preferably via a linker selected from the group

- a)  $-\text{Si}(\text{R}_2)-$
- b)  $-(\text{SiR}_2-\text{O})_n-$   $n=1-10000$
- 5 c)  $-(\text{CHR}-\text{CHR}-\text{O})_n-$   $n=1-10000$
- d)  $-(\text{X})_n-$   $n=1-20$
- e)  $\text{Z}-(\text{X})_n-$   $n=0-20$
- f)  $-(\text{X})_n-\text{W}$   $n=0-20$
- 10 g)  $\text{Z}-(\text{X})_n-\text{W}$   $n=0-20$

10 wherein

R denotes H,  $(\text{C}_1-\text{C}_8)$ -alkyl,  $(\text{C}_6-\text{C}_{18})$ -aryl,  $(\text{C}_7-\text{C}_{19})$ -aralkyl,  $((\text{C}_1-\text{C}_8)$ -alkyl) $_{1-3}$ - $(\text{C}_6-\text{C}_{18})$ -aryl,


X denotes  $(\text{C}_6-\text{C}_{18})$ -arylene,  $(\text{C}_1-\text{C}_8)$ -alkylene,  $(\text{C}_1-\text{C}_8)$ -alkenylene,  $((\text{C}_1-\text{C}_8)$ -alkyl) $_{1-3}$ - $(\text{C}_6-\text{C}_{18})$ -arylene,  $(\text{C}_7-\text{C}_{19})$ -

15 aralkylene,

Z, W denote, independently of one another,  $-\text{C}(=\text{O})\text{O}-$ ,  $-\text{C}(=\text{O})\text{NH}-$ ,  $-\text{C}(=\text{O})-$ , NR, O, CHR,  $\text{CH}_2$ , C=S, S, PR.


Other preferred compounds that can be used as linkers are shown in the following diagram:

20



However, linkers such as e.g. 1,4'-biphenyl, 1,2-ethylene, 1,3-propylene, PEG-(2-10),  $\alpha,\omega$ -siloxanylene or 1,4-phenylene as well as  $\alpha,\omega$ -1,4-bisethylenebenzene or

5 linkers obtainable from siloxanes of the general formula IV are especially preferred.



R:Me, Et  
n = 0 - 10

These can easily be bound to any double bonds present in the polymers and suitable functional groups of the active 10 centres under hydrosilylation conditions (overview of the hydrosilylation reaction by Ojima in The Chemistry of Organic Silicon Compounds, 1989 John Wiley & Sons Ltd., 1480 - 1526).

The size of the polymer enlargement should preferably be 15 calculated such that the actual catalyst (formed from optionally polymer-enlarged ligand and transition metal) dissolves in the solvent to be used, so work can be performed in a homogeneous phase. The polymer-enlarged complex/catalyst used is preferably therefore a 20 homogeneously soluble one. As a result, negative effects, which occur as a result of the phase change of the substrates and products otherwise necessary with the use of heterogeneous catalysts, can be avoided. The polymer-enlarged ligands can have an average molecular weight in 25 the range of 1,000 - 1,000,000, preferably 5,000 - 500,000, particularly preferably 5,000 - 300,000, g/mol.

It lies within the framework of the invention that the above-mentioned components of the polymer-enlarged catalysts (I) to (IV) (polymer, linker, ligand) can be

combined at will in accordance with the knowledge of a person skilled in the art to achieve an optimum reaction.

Combination of polymer enlargement with linker/ligand:

In principle there are two ways in which linkers/ligands

5 can be attached to the polymer enlargement:

a) the active unit causing the chiral induction (ligand)

is bound with an attached linker or directly to a monomer and this is copolymerised with other unmodified monomers, or

10 b) the active unit causing the chiral induction (ligand) is bound with a linker or directly to the finished polymer.

Polymers according to a) or b) can optionally be prepared and block-copolymerised with other polymers, which also

15 exhibit the active units causing the chiral induction (ligand) or which do not exhibit them.

In principle, it is also true for the number of linkers/ligands per monomer in the polymer that as many as possible of these catalytically active units (ligands)

20 should be accommodated in a polymer, so that the conversion per polymer enlargement is increased as a result. On the other hand, however, the ligands should be sufficiently spaced apart so that a reciprocal negative effect on the reactivity (TOF, selectivity) is minimised

25 or completely avoided. Preferably, therefore, the distance between the linkers/ligands in the polymer should be in the range of 1-200 monomer units, preferably 5-25 monomer units.

In an advantageous embodiment, those positions in the

30 polymer or monomer to be polymerised that can readily be functionalised, or allow an existing functionality to be used for the link, are used for attaching the linker/ligand. Thus, heteroatoms or unsaturated carbon atoms are preferably suitable for constructing the link.

In the case of styrene/polystyrene as polymer enlargement, for example, the existing aromatics can be used as connecting points to the linkers/ligands. Functionalities can be readily attached to these aromatics, preferably in

5 3-, 4- or 5- position, particularly preferably in 4-position, by means of standard aromatic chemistry. However, it is also advantageous to mix e.g. already functionalised monomer into the mixture to be polymerised and to bond the linker/ligand to the functionalities 10 present in the polystyrene after the polymerisation. Advantageously suitable for this purpose are e.g. para-hydroxy-, para-chloromethyl- or para-aminostyrene derivatives.

In the case of polyacrylates, an acid group or ester group 15 is present in the monomer component in each case, to which the linker or the active unit can be linked before or after the polymerisation, preferably via an ester or amide bond.

Polysiloxanes as polymer enlargement are preferably 20 constructed in such a way that, in addition to dimethylsilane units, hydromethylsilane units are also present. The linkers/ligands can then also be attached to these positions by a hydrosilylation. These can preferably be linked to the functionalities under 25 consideration in the polymer under hydrosilylation conditions (overview of the hydrosilylation reaction by Ojima in The Chemistry of Organic Silicon Compounds, 1989 John Wiley & Sons Ltd., 1480 - 1526). Suitable polysiloxanes modified in this way are known in 30 the literature ("Siloxane polymers and copolymers" White et al., in Ed. S. Patai "The Chemistry of Organic Silicon Compounds" Wiley, Chichester, 1989, 46, 2954; C. Wandrey et al. TH: Asymmetry 1997, 8, 1975).

Combination of linker with active unit:

That which applies to the joining of polymer to linker/ligand, is synonymously applicable to the attaching of the ligand (active unit) to the linker.

Thus, the linker attachment to the active units can

5 preferably take place via heteroatoms or certain functionalities such as C=O, CH<sub>2</sub>, O, N, S, P, Si or B, ether-/thioether bonds, amine bonds or amide bonds preferably being linked, or esterifications, alkylations, silylations and additions to double bonds being carried

10 out.


Those linking methods already described in the prior art for the polymer enlargement of the monomeric active units are particularly preferred (WO98/35927; Chem. Commun.

1999, 1917; Angew. Chem. 1997, 16, 1835; J. Am. Chem. Soc.


15 1996, 118, 7632; Tetrahedron Lett. 1997, 38, 1527; Eur. J. Org. Chem. 1998, 21; Angew. Chem. 1997, 109, 773; Chem. Commun. 1997, 2353; Tetrahedron: Asymmetry 1995, 6, 2687; ibid 1993, 4, 2351; Tetrahedron Lett. 1995, 36, 1549; Synlett 1999, 8, 1181; Tetrahedron: Asymmetry 1996, 7, 645; Tetrahedron Lett. 1992, 33, 5453; ibid 1994, 35, 6559; Tetrahedron 1994, 50, 11321; Chirality 1999, 11, 745; Tetrahedron Lett. 1991, 32, 5175; Tetrahedron Lett. 1990, 31, 3003; Chem. Commun. 1998, 2435; Tetrahedron Lett. 1997, 38, 2577).

20 25 The production of a polymer-enlarged ligand system or catalyst for the purpose of the invention can also be carried out, in principle, according to the specification in DE10029600.

Ligands of the general formula (III) or (IV)



(III)



(IV)

wherein

A and Q have the meaning in claim 1, R' = H or R, and R, independently of one another in each case, denotes (C<sub>1</sub>-C<sub>8</sub>)-alkyl, HO-(C<sub>1</sub>-C<sub>8</sub>)-alkyl, (C<sub>2</sub>-C<sub>8</sub>)-alkoxyalkyl,

5 (C<sub>6</sub>-C<sub>18</sub>)-aryl, (C<sub>7</sub>-C<sub>19</sub>)-aralkyl, (C<sub>1</sub>-C<sub>8</sub>)-alkyl-(C<sub>6</sub>-C<sub>18</sub>)-aryl, (C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, (C<sub>1</sub>-C<sub>8</sub>)-alkyl-(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl or (C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl-(C<sub>1</sub>-C<sub>8</sub>)-alkyl, are also preferred.

Ligands of the structures (III) and (IV) shown above, in which R is methyl, ethyl, propyl, iso-propyl, tert.-butyl, phenyl, naphthyl, fluorenyl or benzyl, are also preferred.

10 or phenyl, are extremely preferred. Structures in which Q is oxygen or NR', wherein R' is (C<sub>1</sub>-C<sub>8</sub>)-alkyl, (C<sub>6</sub>-C<sub>18</sub>)-aryl or benzyl, and those in which Q is oxygen or NR', wherein R' is methyl, ethyl, propyl, iso-propyl, tert.-butyl, phenyl, naphthyl, fluorenyl or benzyl, are also extremely 15 preferred.

The ligands according to the invention shown should, if possible, possess a high enantiomeric purity. The compounds of formulae (I) to (IV) should preferably possess an enantiomeric enrichment of >90 %, more

20 preferably > 98%.

Another aspect of the invention provided relates to complexes containing the ligands according to the invention with at least one transition metal. Palladium, platinum, rhodium, ruthenium, osmium, iridium, cobalt,

25 nickel or copper, in any catalytically relevant oxidation stage, are suitable as transition metals. These complex compounds are obtainable in solution by simply adding the ligands according to the invention to metal complex precursors, with which the person skilled in the art is 30 familiar.

In another form, the invention also relates to a process for the production of the ligands according to the invention, wherein the corresponding phosphines are obtained by reacting LiP(SiMe<sub>3</sub>)<sub>2</sub> with corresponding co-

35 reactants provided with nucleofuge leaving groups in the

presence of an organometallic base. Alkyl metals, such as e.g. n-, sec-, tert.-BuLi, MeLi, or the like, can be used as the organometallic base.

The trimethylsilylphosphines thus obtained are preferably

5 reacted with the corresponding dihalogen derivative of the structures of group A illustrated above, the halogen atoms each being positioned on the free valencies of the structures shown.

One method of producing a group of the ligands according

10 to the invention will be described below by way of an example. For the sake of clarity, maleic anhydride derivatives were selected in the illustrations, without thereby implying any restrictions or limitations for A.

In general, the procedure is to react an enantiomer-


15 enriched sulfate with a phosphine in the presence of a strong base to form the monophospholane. In another reaction step, the phosphorus-carbon bond is split with the aid of an alkali metal and converted to silyl phospholane by adding a halogen silyl compound. In the 20 following step, the silyl phospholane is reacted with 2,3-dichloromaleic anhydride or a 2,3-dichloromaleamide derivative to form the bisphospholane.

The diol is converted to the dimesylate in the presence of


a nitrogen base and then converted to the phospholane in

25 the presence of  $\text{Li}_2\text{PPh}_3$ -THF (Tetrahedron Asymmetry 1991, 2, 569-592).


13




The phospholane is also obtained by reacting the cyclic sulfate with  $\text{H}_2\text{PPh}$  in the presence of an alkali metal hydride (*J. Am. Chem. Soc.* 1999, 121, 9899-9900).



5 Another alternative preparation of the phospholane is achieved by reacting the cyclic sulfate with phenylphosphine in the presence of butyllithium.




10 After splitting the  $\text{Ph-P}$  bond with elementary lithium, the  $\text{P-silylated}$  compound is obtained by adding trimethylsilyl chloride.




An alternative synthesis route involves the reaction of the cyclic sulfate with lithium bis(trimethylsilyl)-

5 phosphine (Organometallics 2000, 19, 250). Instead of the methanolysis of the phosphorus-silicon bonds described by Burk et al., it has proved advantageous in the synthesis of the ligands according to the invention to perform ring closure by adding methyllithium to form the  
 10 trimethylsilyl-substituted phospholane.



In both reaction routes, the formation of the trimethylsilyl-substituted phospholane in meso-form is observed as a side reaction.

In the following step, the reaction of silyl phospholane with a 2,3-dichloromaleic acid derivative takes place analogously to a coupling reaction of Fenske et al. and  
 5 Kinting et al. (Chem. Ber. 1974, 107, 117; J. Organomet. Chem. 1986, 302, 259).



The purification of the ligand takes place by the formation of the metal complex. Here, surprisingly, it has  
 10 been found that a complex is obtained in optically pure form from the diastereomeric mixture of the ligand-metal compounds.

The compounds of the general formulae (I) - (IV) can be used as ligands for complex compounds in asymmetric, 15 metal-catalysed reactions (such as e.g. hydrogenation, hydroformylation, rearrangement, allylic alkylation, cyclopropanation, hydrosilylation, hydride transfers, hydroborations, hydrocyanations, hydrocarboxylations, aldol reactions or Heck reaction). They are particularly  
 20 suitable for asymmetric reactions.

Suitable complexes, particularly of the general formula (V), contain ligands according to the invention of formulae (I) - (IV) as ligands,



wherein, in general formula (V), M denotes a metal centre, preferably a transition metal centre, L denotes the same or different, coordinating, organic or inorganic ligands

- 5 and P denotes bidentate organophosphorus ligands of formulae (I) - (IV) according to the invention, S represents coordinating solvent molecules and A represents equivalents of non-coordinating anions, wherein x and y are whole numbers greater than or equal to 1, and z, q
- 10 and r are whole numbers greater than or equal to 0.

The sum of y + z + q has an upper limit set by the coordination centres available at the metal centres, it being unnecessary for all the coordination positions to be occupied. Complex compounds with an octahedral, pseudo-octahedral, tetrahedral, pseudo-tetrahedral or square-planar coordination sphere, which can also be distorted around the transition metal centre in each case, are preferred. The sum of y + z + q is less than or equal to 6 in these complex compounds.

- 15
- 20 The complex compounds according to the invention contain at least one metal atom or ion, preferably a transition metal atom or ion, particularly of palladium, platinum, rhodium, ruthenium, osmium, iridium, cobalt, nickel or copper in any catalytically relevant oxidation stage.
- 25 Complex compounds with fewer than four metal centres are preferred, and those with one or two metal centres are particularly preferred. The metal centres can be occupied by various metal atoms and/or ions.

- 30 Preferred ligands L of these complex compounds are halide, particularly Cl, Br and I, diene, particularly cyclooctadiene, norbornadiene, olefin, particularly ethylene and cyclooctene, acetato, trifluoroacetato, acetylacetonato, allyl, methallyl, alkyl, particularly

methyl and ethyl, nitrile, particularly acetonitrile and benzonitrile, and also carbonyl and hydrido ligands.

Preferred coordinating solvents S are amines, particularly triethylamine, alcohols, particularly methanol and

5 aromatics, particularly benzene and cumene.

Preferred non-coordinating anions A are trifluoroacetate, trifluoromethane sulfonate,  $\text{BF}_4^-$ ,  $\text{ClO}_4^-$ ,  $\text{PF}_6^-$ ,  $\text{SbF}_6^-$  and  $\text{BAr}_4^-$ .

Different molecules, atoms or ions of the individual components M, P, L, S and A can be contained in the

10 individual complex compounds.

Among the ionically constructed complex compounds, compounds of the  $[\text{RhP}(\text{diene})]^-\text{A}^-$  type are preferred, wherein P represents a ligand of formulae (I) - (IV) according to the invention.

15 The preparation of these metal-ligand complex compounds can take place *in situ* by the reaction of a metal salt or a corresponding pre-complex with the ligands of the general formulae (I) - (IV). In addition, a metal-ligand complex compound can be obtained by reaction of a metal  
20 salt or a corresponding pre-complex with the ligands of the general formulae (I) - (IV) and subsequent isolation.

Examples of the metal salts are metal chlorides, bromides, iodides, cyanides, nitrates, acetates, acetylacetones, hexafluoroacetylacetones, tetrafluoroborates,

25 perfluoroacetates or triflates, particularly of palladium, platinum, rhodium, ruthenium, osmium, iridium, cobalt, nickel or copper.

Examples of the pre-complexes are:

Cyclooctadienepalladium chloride, cyclooctadienepalladium

30 iodide,

1,5-hexadienepalladium chloride, 1,5-hexadienepalladium iodide, bis(dibenzylideneacetone)palladium, bis(acetonitrile)palladium(II) chloride, bis(acetonitrile)palladium(II) bromide,

5 bis(benzonitrile)palladium(II) chloride, bis(benzonitrile)palladium(II) bromide, bis(benzonitrile)palladium(II) iodide, bis(allyl)palladium, bis(methallyl)palladium, allylpalladium chloride dimer, methallylpalladium chloride dimer, tetramethylethylenediaminepalladium dichloride, tetramethylethylenediaminepalladium dibromide, tetramethylethylenediaminepalladium diiodide, tetramethylethylenediaminepalladium dimethyl, cyclooctadieneplatinum chloride, cyclooctadieneplatinum iodide, 1,5-hexadieneplatinum chloride, 1,5-hexadieneplatinum iodide, bis(cyclooctadiene)platinum, potassium (ethylenetrichloroplatinate), cyclooctadienerhodium(I) chloride dimer, norbornadienerhodium(I) chloride dimer,

20 1,5-hexadienerhodium(I) chloride dimer, tris(triphenylphosphane)rhodium(I) chloride, hydridocarbonyltris(triphenylphosphane)rhodium(I) chloride, bis(cyclooctadiene)rhodium(I) perchlorate, bis(cyclooctadiene)rhodium(I) tetrafluoroborate, bis(cyclooctadiene)rhodium(I) triflate, bis(acetonitrilecyclooctadiene)rhodium(I) perchlorate, bis(acetonitrilecyclooctadiene)rhodium(I) tetrafluoroborate,

25 bis(acetonitrilecyclooctadiene)rhodium(I) triflate, bis(acetonitrilecyclooctadiene)rhodium(III) chloride dimer, pentamethylcyclopentadienerhodium(III) chloride dimer,

(cyclooctadiene)Ru( $\eta^3$ -allyl)<sub>2</sub>,  
((cyclooctadiene)Ru)<sub>2</sub>(acetate)<sub>4</sub>,  
((cyclooctadiene)Ru)<sub>2</sub>(trifluoroacetate)<sub>4</sub>, RuCl<sub>2</sub>(arene)  
dimer, tris(triphenylphosphane)ruthenium(II) chloride,  
5 cyclooctadieneruthenium(II) chloride, OsCl<sub>2</sub>(arene) dimer,  
cyclooctadieneiridium(I) chloride dimer,  
bis(cyclooctene)iridium(I) chloride dimer,  
bis(cyclooctadiene)nickel, (cyclododecatriene)nickel,  
tris(norbornene)nickel, nickel tetracarbonyl, nickel(II)  
10 acetylacetone,  
(arene)copper triflate, (arene)copper perchlorate,  
(arene)copper trifluoroacetate, cobalt carbonyl.

The complex compounds based on one or more metals of the metallic elements, particularly from the group of Ru, Co,  
15 Rh, Ir, Ni, Pd, Pt and Cu, can already be catalysts or can be used to produce catalysts based on one or more metals of the metallic elements, particularly from the group of Ru, Co, Rh, Ir, Ni, Pd, Pt and Cu. All these complex compounds are particularly suitable in the asymmetric  
20 hydrogenation of C=C-, C=O- or C=N-bonds, in which they exhibit high activities and selectivities, and in asymmetric hydroformylation. In particular, it proves advantageous here that the ligands of the general formulae (I) - (IV) can be very well adapted, sterically and  
25 electronically, to the particular substrate and the catalytic reaction owing to their simple, broad adaptability.

Corresponding catalysts contain at least one of the complex compounds according to the invention.

30 As already indicated, the use of the complexes or catalysts according to the invention is particularly suitable for the hydrogenation of E/Z mixtures of prochiral N-acylated  $\beta$ -aminoacrylic acids or their derivatives. Acetyl, formyl or urethane or carbamoyl

protective groups can preferably be used here as the acyl group.

In principle, the ligands and complexes/catalysts are used in a way known to the person skilled in the art in the

5 form of transfer hydrogenation ("Asymmetric transfer hydrogenation of C=O and C=N bonds", M. Wills et al. *Tetrahedron: Asymmetry* 1999, 10, 2045; "Asymmetric transfer hydrogenation catalyzed by chiral ruthenium complexes" R. Noyori et al. *Acc. Chem. Res.* 1997, 30, 97;

10 "Asymmetric catalysis in organic synthesis", R. Noyori, John Wiley & Sons, New York, 1994, p.123; "Transition metals for organic Synthesis" Ed. M. Beller, C. Bolm, Wiley-VCH, Weinheim, 1998, vol. 2, p.97; "Comprehensive Asymmetric Catalysis" Ed.: Jacobsen, E.N.; Pfaltz, A.;

15 Yamamoto, H., Springer-Verlag, 1999), but it can also proceed conventionally with elemental hydrogen. The process can thus operate either by hydrogenation with hydrogen gas or by transfer hydrogenation.

In enantioselective hydrogenation, the preferred procedure

20 is to dissolve the substrate to be hydrogenated and the complex/catalyst in a solvent. The catalyst is preferably formed from a pre-catalyst as indicated above, in the presence of the chiral ligand, by reaction or by pre-hydrogenation before the substrate is added. Hydrogenation

25 is then performed at 0.1 to 10 bar, preferably 0.5 to 5 bar, hydrogen pressure.

The temperature during hydrogenation should be selected such that the reaction proceeds sufficiently rapidly with the desired enantiomeric excesses, but side reactions are

30 avoided as far as possible. It is advantageous to work at temperatures of -20°C to 100°C, preferably 0°C to 50°C. The ratio of substrate to catalyst is determined by economic factors. The reaction should be carried out sufficiently rapidly with the lowest possible

35 complex/catalyst concentration. However, it is preferable

to work with a substrate/catalyst ratio of between 10000:1 and 10:1, preferably 1000:1 and 50:1.

The use of the polymer-enlarged ligands or complexes is advantageous in catalytic processes carried out in a

5 membrane reactor. The continuous operation that is possible in this apparatus, in addition to batch and semi-continuous operation, can be carried out in the cross-flow filtration mode (Fig. 2) or as dead-end filtration (Fig. 1), as desired.

10 Both process variants are described in principle in the prior art (Engineering Processes for Bioseparations, Ed.: L.R. Weatherley, Heinemann, 1994, 135-165; Wandrey et al., *Tetrahedron Asymmetry* 1999, 10, 923-928).

For a complex/catalyst to appear suitable for use in a

15 membrane reactor, it has to fulfil many different criteria. On the one hand, for example, it should be ensured that there must be a sufficiently high retention capacity for the polymer-enlarged complex/catalyst so that there is satisfactory activity in the reactor over a

20 desired period, without complex/catalyst having to be continually added, which is disadvantageous from the point of view of process economy (DE19910691). In addition, the catalyst used must have an appropriate tof (turn over frequency), to be able to convert the substrate into the

25 product within economically reasonable periods.

In general the  $\beta$ -amino acid precursors were prepared in accordance with specifications from the literature. For the syntheses of the compounds, guidance can be taken from the general specifications by Zhang et al. (G. Zhu, Z.

30 Chen, X. Zhang J. Org. Chem. 1999, 64, 6907-6910) and Noyori et al. (W. D. Lubell, M. Kitamura, R. Noyori *Tetrahedron: Asymmetry* 1991, 2, 543-554) and also Melillo et al. (D. G. Melillo, R. D. Larsen, D. J. Mathre, W. F. Shukis, A. W. Wood, J. R. Colleluori J. Org. Chem. 1987

35 52, 5143-5150). Starting from the corresponding 3-

ketocarboxylates, the desired prochiral enamides were obtained by reaction with ammonium acetate and subsequent acylation. The hydrogenation products can be converted to the  $\beta$ -amino acids by measures known to the person skilled

5 in the art (analogous to the  $\alpha$ -amino acids).

Within the framework of the invention, mixtures of polymer-enlarged polymers refer to the fact that individual polymers of different origins are polymerised together into block polymers. Random mixtures of the

10 monomers in the polymer are also possible.

Polymer enlargement within the framework of the invention refers to the fact that one or more active units causing chiral induction (ligands) are copolymerised in a suitable form with other monomers or that these ligands are

15 attached to an existing polymer by methods known to the person skilled in the art. Forms of the units suitable for copolymerisation are well known to the person skilled in the art and can be freely selected by him. The procedure is preferably such that the molecule in question is

20 derivatised with groups capable of copolymerisation, according to the type of copolymerisation, e.g. in the case of copolymerisation with (meth)acrylates, by attaching to acrylate molecules.

Methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl,  
25 *sec*-butyl, *tert*-butyl, pentyl, hexyl, heptyl or octyl, together with all their bond isomers, can be considered as  $(C_1-C_8)$ -alkyl radicals.

The  $(C_1-C_8)$ -alkoxy radical corresponds to the  $(C_1-C_8)$ -alkyl radical, with the proviso that this is bonded to the  
30 molecule via an oxygen atom.

As  $(C_2-C_8)$ -alkoxyalkyl, radicals in which the alkyl chain is interrupted by at least one oxygen function are meant, wherein two oxygen atoms cannot be joined to one another. The number of carbon atoms gives the total number of  
35 carbon atoms contained in the radical.

A (C<sub>3</sub>-C<sub>5</sub>)-alkylene bridge is a carbon chain with three to five C atoms, this chain being bonded to the molecule in question via two different C atoms.

The radicals just described can be mono- or

5 polysubstituted with halogens and/or radicals containing N, O, P, S or Si atoms. These are particularly alkyl radicals of the type mentioned above having one or more of these heteroatoms in their chain or being bonded to the molecule via one of these heteroatoms.

10 (C<sub>3</sub>-C<sub>8</sub>)-Cycloalkyl means cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl radicals etc. These can be substituted with one or more halogens and/or radicals containing N, O, P, S or Si atoms and/or can have N, O, P or S atoms in the ring, such as e.g. 1-, 2-, 3-, 15 4-piperidyl, 1-, 2-, 3-pyrrolidinyl, 2-, 3-tetrahydrofuryl, 2-, 3-, 4-morpholinyl.

A (C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl-(C<sub>1</sub>-C<sub>8</sub>)-alkyl radical refers to a cycloalkyl radical as set out above, which is bonded to the molecule via an alkyl radical as stated above.

20 (C<sub>1</sub>-C<sub>8</sub>)-Acyloxy within the framework of the invention means an alkyl radical as defined above with a maximum of 8 C atoms, which is bonded to the molecule via a COO- function.

25 (C<sub>1</sub>-C<sub>8</sub>)-Acyl within the framework of the invention means an alkyl radical as defined above with a maximum of 8 C atoms, which is bonded to the molecule via a CO- function.

A (C<sub>6</sub>-C<sub>18</sub>)-aryl radical is understood to mean an aromatic radical with 6 to 18 C atoms. These include in particular compounds such as phenyl, naphthyl, anthryl, phenanthryl 30 or biphenyl radicals, or systems of the type described above annelated to the molecule in question, such as e.g. indenyl systems, which can optionally be substituted with (C<sub>1</sub>-C<sub>8</sub>)-alkyl, (C<sub>1</sub>-C<sub>8</sub>)-alkoxy, NR<sup>1</sup>R<sup>2</sup>, (C<sub>1</sub>-C<sub>8</sub>)-acyl or (C<sub>1</sub>-C<sub>8</sub>)-acyloxy.

A (C<sub>7</sub>-C<sub>19</sub>)-aralkyl radical is a (C<sub>6</sub>-C<sub>18</sub>)-aryl radical bonded to the molecule via a (C<sub>1</sub>-C<sub>8</sub>)-alkyl radical.

A (C<sub>3</sub>-C<sub>18</sub>)-heteroaryl radical within the framework of the invention refers to a five-, six- or seven-membered

5 aromatic ring system of 3 to 18 C atoms, which contains heteroatoms such as e.g. nitrogen, oxygen or sulfur in the ring. In particular, radicals such as 1-, 2-, 3-furyl, such as 1-, 2-, 3-pyrrolyl, 1-, 2-, 3-thienyl, 2-, 3-, 4-pyridyl, 2-, 3-, 4-, 5-, 6-, 7-indolyl, 3-, 4-, 10 5-pyrazolyl, 2-, 4-, 5-imidazolyl, acridinyl, quinolinyl, phenanthridinyl and 2-, 4-, 5-, 6-pyrimidinyl are considered as such heteroaromatics.

A (C<sub>4</sub>-C<sub>19</sub>)-heteroaralkyl means a heteroaromatic system corresponding to the (C<sub>7</sub>-C<sub>19</sub>)-aralkyl radical.

15 Fluorine, chlorine, bromine and iodine are suitable as halogens (Hal).

PEG means polyethylene glycol.

The term enantiomer-enriched or enantiomeric excess within the framework of the invention means the proportion of an

20 enantiomer in a mixture with its optical antipode in a range of >50 % and <100 %. The ee value is calculated as follows:

$([\text{Enantiomer1}]-[\text{Enantiomer2}])/([\text{Enantiomer1}]+[\text{Enantiomer2}])=\text{ee value}$

25 The naming of the complexes and ligands according to the invention contains, within the framework of the invention, all possible diastereomers, the two optical antipodes of any diastereomer also being included therein.

The complexes and catalysts described here determine, with their configuration, the optical induction in the product.

30 It goes without saying that the catalysts, when used racemically, also yield racemic product. A subsequent resolution of racemates then yields the enantiomer-

enriched products again. However, this is part of the general knowledge of the person skilled in the art.

N-Acyl groups mean protective groups that are conventionally used in amino acid chemistry for the

5 protection of nitrogen atoms. The following can be particularly mentioned in this capacity: formyl, acetyl, Moc, Eoc, phthalyl, Boc, Alloc, Z, Fmoc, etc.

The literature references cited in this document are deemed to be contained in the disclosure.

10 Within the framework of the invention, membrane reactor means any reaction vessel in which the molecular weight-enlarged catalyst is enclosed in a reactor while low molecular weight substances are fed into the reactor or can leave it. The membrane can be integrated directly into

15 the reaction chamber or can be installed outside it in a separate filtration module, in which the reaction solution flows continuously or intermittently through the filtration module and the retentate is recycled into the reactor. Suitable embodiments are described in WO98/22415

20 and in Wandrey et al. in Jahrbuch 1998, Verfahrenstechnik und Chemieingenieurwesen, VDI p. 151 ff.; Wandrey et al. in Applied Homogeneous Catalysis with Organometallic Compounds, Vol. 2, VCH 1996, p. 832 ff.; Kragl et al., Angew. Chem. 1996, 6, 684 f., among others.

25 Within the framework of the invention, a polymer-enlarged ligand/complex means one in which the molecular weight-enlarging polymer is covalently bonded to the ligand.

**Descriptions of the drawings:**

Fig. 1 shows a membrane reactor with dead-end filtration. The substrate 1 is transferred via a pump 2 into the reactor chamber 3, which has a membrane 5. In the 5 agitator-driven reactor chamber, in addition to the solvent, the catalyst 4, the product 6 and unreacted substrate 1 are found. Mainly low-molecular weight substances 6 are filtered off through the membrane 5.

Fig. 2 shows a membrane reactor with cross-flow 10 filtration. Here, the substrate 7 is transferred via the pump 8 into the agitated reactor chamber, in which solvent, catalyst 9 and product 14 are also found. By means of the pump 16 a solvent flow is set up, which passes via an optionally present heat exchanger 12 into 15 the cross-flow filtration cell 15. Here the low molecular-weight product 14 is separated off by means of the membrane 13. High molecular-weight catalyst 9 is then passed back into the reactor 10 with the solvent flow, optionally via a heat exchanger 12 again, optionally via 20 the valve 11.

**Examples:****General**

Reactions of air-sensitive compounds were performed in an argon-filled glove box or in standard Schlenk tubes.

- 5 Solvents tetrahydrofuran (THF), diethyl ether and dichloromethane were degassed and purified by means of solvent-drying equipment (Innovative Technologies) by filtration through a column filled with activated aluminium oxide; toluene and pentane were additionally freed of oxygen by a column filled with a copper catalyst.
- 10

The following examples serve to explain the invention. They are not in any way intended to represent a limitation.

**Example 1: (*R,R*)-2,5-Dimethyl-1-phenyl-phospholane**

- 15 One equivalent of *n*-BuLi (8.9 ml, 1.6 M. solution in *n*-hexane) is added slowly to a solution of 1.57 g phenylphosphine (14.3 mmol) in 100 ml of THF at -78 °C. This is then stirred for a further two hours at room temperature. After cooling again to -78 °C, one equivalent
- 20 of the cyclic sulfate 1 in 10 ml of THF is added via a cannula and the reaction is allowed to end by stirring at 25°C for 3 hours. Before adding a further 1.2 eq. of *n*-BuLi (9.8 ml) via syringe, the mixture is cooled again, *n*-BuLi is added and stirring is continued overnight. For the
- 25 work-up, the solvent was drawn off in vacuo and the residue taken up in 5 ml of water and extracted with 50 ml of methylene chloride. After the phase separation the solvent is removed and the residue is distilled in vacuo. An almost colourless syrup is obtained in a yield of 71 %
- 30 (1.95 g).

BP<sub>0.7</sub> = 105°C; <sup>1</sup>H-NMR (CDCl<sub>3</sub>): 7.51-7.45 (2H, m, arom. H), 7.35-7.30 (3H, m, arom. H), 2.70 (1H, m, CH-P), 2.31 (1H, m, H<sub>a</sub>-CH<sub>2</sub>), 2.22 (1H, m, CH-P), 1.97 (1H, m, H<sub>b</sub>-CH<sub>2</sub>), 1.47 (1H, m, H<sub>a</sub>-CH<sub>2</sub>), 1.34 (1H, m, H<sub>b</sub>-CH<sub>2</sub>), 1.33 (3H, dd, CH<sub>3</sub>, 5 <sup>3</sup>J<sub>H,P</sub> = 19.0 Hz, <sup>3</sup>J<sub>H,H</sub> = 7.1 Hz), 0.79 (3H, dd, CH<sub>3</sub>, <sup>3</sup>J<sub>H,P</sub> = 11.5 Hz, <sup>3</sup>J<sub>H,H</sub> = 7.1 Hz); <sup>13</sup>C-NMR (in CDCl<sub>3</sub>): 137.7 (d, ipso-C, <sup>1</sup>J<sub>C,P</sub> = 25.7 Hz), 134.1 (d, ortho-C, <sup>2</sup>J<sub>C,P</sub> = 18.1 Hz), 128.4 (s, para-C), 127.8 (d, meta-C, <sup>3</sup>J<sub>C,P</sub> = 6.6 Hz), 36.9 (d, CH<sub>2</sub>, <sup>2</sup>J<sub>C,P</sub> = 3.8 Hz), 36.8 (s, CH<sub>2</sub>), 35.3 (d, CH-P, <sup>1</sup>J<sub>C,P</sub> = 11.4 Hz), 34.8 (d, CH-P, <sup>1</sup>J<sub>C,P</sub> = 8.6 Hz), 21.0 (d, CH<sub>3</sub>, <sup>2</sup>J<sub>C,P</sub> = 33.4 Hz), 15.1 (s, CH<sub>3</sub>); <sup>31</sup>P-NMR (in CDCl<sub>3</sub>): 10.9; C<sub>12</sub>H<sub>17</sub>P (192.237).

**Example 2: (R,R)-2,5-Dimethyl-1-trimethylsilyl-phospholane**

15 According to the specification by Burk et al. (Tetrahedron: Asymmetry 1991, 2, 569-592), 3.06 g (15.9 mmol) of (R,R)-2,5-dimethyl-1-phenyl-phospholane in approx. 100 ml THF is taken at room temperature and 2.5 equivalents of lithium are added. The mixture is stirred 20 overnight. The resulting deep-red suspension is separated from the lithium using a cannula and 2 equivalents of chlorotrimethylsilane (3.46 g) are slowly added at 0°C using a syringe. Towards the end of the reaction, the reaction solution becomes almost colourless. The solution 25 is concentrated in vacuo to 60-70% of its volume and the precipitated lithium salts are filtered off. After complete evaporation, the residue is distilled under reduced pressure and the silyl compound is obtained in a yield of 1.43 g (48%) as a colourless, liquid compound. 30 The <sup>31</sup>P-NMR spectrum discloses the presence of two species in a ratio of approx. 3:1. Based on an evaluation of the NMR signals, it is obviously the desired chiral silyl phospholane and the corresponding meso-compound. Isomerisation reactions of this type have already been 35 described by Burk (Tetrahedron: Asymmetry 1991, 2,

569-592). Since, in the subsequent reaction with dichloromaleic anhydride, only one diastereomer crystallises out, this mixture of isomers could be used for the nucleophilic reaction without prior separation.

5

Bp<sub>15</sub> = 72-80°C; <sup>1</sup>H-NMR (CDCl<sub>3</sub>): 2.54-1.20 (6H, m, CH-P, CH<sub>2</sub>), 1.25-1.15 (6H, m, CH<sub>3</sub>), 0.20 (d, Si(CH<sub>3</sub>)<sub>3</sub>, <sup>3</sup>J<sub>H,P</sub> = 4.2 Hz), 0.15 (d, meso-Si(CH<sub>3</sub>)<sub>3</sub>, <sup>3</sup>J<sub>H,P</sub> = 4.2 Hz); <sup>13</sup>C-NMR (in CDCl<sub>3</sub>): 40.1 (d, CH<sub>2</sub>, <sup>2</sup>J<sub>C,P</sub> = 4.8 Hz), 38.9 (s, CH<sub>2</sub>), 37.5 (s, meso-CH<sub>2</sub>), 33.6 (d, CH-P, <sup>1</sup>J<sub>C,P</sub> = 11.4 Hz), 31.3 (d, CH-P, <sup>1</sup>J<sub>C,P</sub> = 7.6 Hz), 30.5 (d, meso-CH-P, <sup>1</sup>J<sub>C,P</sub> = 7.6 Hz), 23.4 (d, meso-CH<sub>3</sub>, <sup>2</sup>J<sub>C,P</sub> = 30.5 Hz), 22.8 (d, CH<sub>3</sub>, <sup>2</sup>J<sub>C,P</sub> = 30.5 Hz), 18.0 (d, CH<sub>3</sub>, <sup>2</sup>J<sub>C,P</sub> = 1.9 Hz), -0.2 (d, Si(CH<sub>3</sub>)<sub>3</sub>, <sup>2</sup>J<sub>C,P</sub> = 11.4 Hz), -1.8 (d, meso-Si(CH<sub>3</sub>)<sub>3</sub>, <sup>2</sup>J<sub>C,P</sub> = 10.5 Hz); <sup>31</sup>P-NMR (in CDCl<sub>3</sub>): -53.1 (meso), -54.5; C<sub>9</sub>H<sub>21</sub>PSi (188,322);

**Example 3: (R,R)-2,5-Dimethyl-1-trimethylsilyl-phospholane**

To a solution of 9.50 g of tris(trimethylsilyl)phosphine (37.9 mmol) in 300 ml of THF are added 1.05 eq. of MeLi (28.4 ml, 1.4 M solution in ether), slowly, at room temperature. Stirring is then continued overnight at room temperature and the solvent is then removed under vacuum. The residue is now taken up with 300 ml of ether and one equivalent of the cyclic sulfate is added (6.83 g in 100 ml of ether) dropwise to the lithium salt solution. After three hours, 28.4 ml of MeLi solution are again added to the reaction mixture using a syringe. To complete the reaction, the mixture is stirred overnight. For the workup, the solvent is removed in vacuo and the residue is carefully distilled in vacuo. A colourless, mobile syrup is obtained in a yield of 70% (5.0 g).

Bp<sub>20</sub> = 93°C; <sup>1</sup>H-NMR (CDCl<sub>3</sub>): 2.54-1.20 (6H, m, CH-P, CH<sub>2</sub>), 1.25-1.15 (6H, m, CH<sub>3</sub>), 0.20 (9H, d, Si(CH<sub>3</sub>)<sub>3</sub>, <sup>3</sup>J<sub>H,P</sub> = 4.2

Hz),  $^{13}\text{C}$ -NMR (in  $\text{CDCl}_3$ ): 40.1 (d,  $\text{CH}_2$ ,  $^2\text{J}_{\text{C},\text{P}} = 4.8$  Hz), 38.9 (s,  $\text{CH}_2$ ), 33.6 (d,  $\text{CH-P}$ ,  $^1\text{J}_{\text{C},\text{P}} = 11.4$  Hz), 31.3 (d,  $\text{CH-P}$ ,  $^1\text{J}_{\text{C},\text{P}} = 7.6$  Hz), 22.8 (d,  $\text{CH}_3$ ,  $^2\text{J}_{\text{C},\text{P}} = 30.5$  Hz), 18.0 (d,  $\text{CH}_3$ ,  $^2\text{J}_{\text{C},\text{P}} = 1.9$  Hz), -0.2 (d,  $\text{Si}(\text{CH}_3)_3$ ,  $^2\text{J}_{\text{C},\text{P}} = 11.4$  Hz),  $^{31}\text{P}$ -NMR 5 (in  $\text{CDCl}_3$ ): -54.5;  $\text{C}_{9}\text{H}_{21}\text{PSi}$  (188,322);

**Example 4: 2,3-Bis[(*R,R*)-2,5-dimethyl-phospholanyl]maleic anhydride**

According to the specification by Fenske et al. (Chem. Ber. 1974, 107, 117-122) 450 mg (2.4 mmol) of the 10 diastereomeric mixture of the silyl compound 3 were added dropwise using a syringe over a period of 15 minutes to a solution of 200 mg of 2,3-dichloromaleic anhydride (0.5 eq.) in 5 ml of diethyl ether at 0°C. The mixture was then 15 kept at -78°C overnight. The dark reddish-brown crystals that precipitated were isolated from the solvent by bag filtration and then dried. Yield 190 mg (49%).

In the NMR of the isolated compound, only one diastereomer of a  $C_2$ -symmetrical compound is found. This is the proof 20 that the corresponding meso-silylphosphine, which was added to the reaction in a deficiency, either has not reacted or the corresponding diastereomeric products do not crystallise out. With this observation, a partial racemisation in the synthesis of the (*R,R*)-2,5-dimethyl-1- 25 trimethylsilyl-phospholane can also be simultaneously ruled out. Its use should lead to diastereomeric bisphospholanes after phosphorylation, and these were not detected.

$^1\text{H}$ -NMR ( $\text{CDCl}_3$ ): 3.32 (2H, m,  $\text{CH}_2$ ), 2.49-1.25 (10H, m,  $\text{CH-P}$ , 30  $\text{CH}_2$ ), 1.22 (6H, dd,  $\text{CH}_3$ ,  $^3\text{J}_{\text{H},\text{P}} = 20.4$  Hz,  $^3\text{J}_{\text{H},\text{H}} = 7.3$  Hz), 1.07 (6H, dd,  $\text{CH}_3$ ,  $^3\text{J}_{\text{H},\text{P}} = 10.5$  Hz,  $^3\text{J}_{\text{H},\text{H}} = 7.2$  Hz);  $^{13}\text{C}$ -NMR (in  $\text{CDCl}_3$ ): 163.7 (s,  $\text{C=O}$ ), 37.7 (s,  $\text{CH}_2$ ), 36.9 (s,  $\text{CH}_2$ ), 36.6 (m,  $\text{CH-P}$ ), 31.5 (s,  $\text{CH-P}$ ), 20.5 (m,  $\text{CH}_3$ ), 16.9 (s,  $\text{CH}_3$ );  $^{31}\text{P}$ -NMR (in  $\text{CDCl}_3$ ): -2.2;  $\text{C}_{16}\text{H}_{24}\text{O}_3\text{P}_2$  (326,307);

**Example 5: Rhodium complexes by reaction of the ligand with  $[\text{Rh}(\text{COD})_2]\text{BF}_4$**

190 mg (0.58 mmol) of the bisphospholane are dissolved in

5 2 ml of THF and slowly added at approx. -20°C to a solution of one equivalent of  $[\text{Rh}(\text{COD})_2]\text{BF}_4$  (236 mg). This is left to warm up to room temperature and stirred for a further 90 min. A brown precipitate slowly forms, which is washed twice with ether after being filtered off.

10  $^1\text{H-NMR}$  (acetone- $d_6$ ): 5.85 (2H, s(br), =CH), 5.15 (2H, s(br), =CH), 3.07 (2H, m, CH-P), 2.67-1.50 (18 H, m, CH-P,  $\text{CH}_2$ ), 1.57 (6H, dd,  $\text{CH}_3$ ,  $^3J_{\text{H,P}} = 19.5$  Hz,  $^3J_{\text{H,H}} = 7.0$  Hz), 1.23 (6H, dd,  $\text{CH}_3$ ,  $^3J_{\text{H,P}} = 16.0$  Hz,  $^3J_{\text{H,H}} = 7.1$  Hz);  $^{13}\text{C-NMR}$  (in acetone- $d_6$ ): 165.1 (m, C=C), 160.1 (m, C=O), 108.5

15 (=CH), 94.9 (=CH), 40.8 (m, CH-P), 38.0 (m, CH-P), 37.7 (s,  $\text{CH}_3$ ), 36.4 (s,  $\text{CH}_2$ ), 32.8 (s,  $\text{CH}_2$ ), 29.0 (s,  $\text{CH}_2$ ), 17.6 (m,  $\text{CH}_3$ ), 14.1 (s,  $\text{CH}_3$ );  $^{31}\text{P-NMR}$  (in  $\text{CDCl}_3$ ): 63.8 (d,  $^1J_{\text{P,Rh}} = 151$  Hz,  $[\text{Rh}(\text{P-P})(\text{COD})]\text{BF}_4$ );





**Example 6: Hydrogenations**

Conditions: Catalyst : substrate: 200 : 1; 1 mmol substrate, 15 ml methanol or THF, 25°C, 1.5 bar hydrogen.

Substrate	THF		Methanol	
	t (sample)	% ee / conversion	t (sample)	% ee / conversion
Methyl acetamido-cinnamate	2 h	95.5 (R) 100 %	0.5 h	84.0 (R) 25 %
	6 h	95.5 (R) 100 %	1 h	87.4 (R) 50 %
	24 h	95.5 (R) 100 %	2 h	88.9 (R) 90 %
Dimethyl itaconate	0.5 h	80.4 (S) 20 %	1 h	2.9 (S) 20 %
	1 h	79.1 (S) 50 %	2 h	4.1 (S) 55 %
	2 h	73.3 (S) 100 %	4 h	3.1 (S) 100 %


Example 7: Hydrogenations of  $\beta$ -amino acid precursors

Conditions: 0.005 mmol catalyst, 0.5 mmol substrate,  
7.5 ml solvent, 1 bar hydrogen, 25°C

Substrate	Solvent	Catalyst (Example 4)	[Rh((S,S)-Me-DuPHOS)(COD)]BF <sub>4</sub>
	MeOH	85%ee (S)	78%ee (R)
	THF	82%ee (S)	73%ee (R)
	MeOH	69%ee (S)	4%ee (R)
	THF	63%ee (S)	36%ee (R)
	MeOH	97%ee (S)	99%ee (R)
	THF	99%ee (S)	98%ee (R)
	MeOH	81%ee (S)	68%ee (R)

## Claims:

1. Enantiomer-enriched bidentate organophosphorus ligands of the general formula (I),



5


wherein

$R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ , independently of one another, denote  $(C_1-C_8)$ -alkyl,  $(C_2-C_8)$ -alkoxyalkyl,  $(C_6-C_{18})$ -aryl,  $(C_7-C_{19})$ -aralkyl,  $(C_3-C_{18})$ -heteroaryl,

10  $(C_4-C_{19})$ -heteroaralkyl,  $(C_1-C_8)$ -alkyl- $(C_6-C_{18})$ -aryl,  $(C_1-C_8)$ -alkyl- $(C_3-C_{18})$ -heteroaryl,  $(C_3-C_8)$ -cycloalkyl,  $(C_1-C_8)$ -alkyl- $(C_3-C_8)$ -cycloalkyl,  $(C_3-C_8)$ -cycloalkyl- $(C_1-C_8)$ -alkyl, or  $R^1$  and  $R^2$  and/or  $R^3$  and  $R^4$  represent a  $(C_3-C_5)$ -alkylene bridge mono or polysubstituted with

15  $(C_1-C_8)$ -alkyl,  $HO-(C_1-C_8)$ -alkyl,  $(C_1-C_8)$ -alkoxy,  $(C_2-C_8)$ -alkoxyalkyl,  $(C_6-C_{18})$ -aryl,  $(C_7-C_{19})$ -aralkyl,  $(C_1-C_8)$ -alkyl- $(C_6-C_{18})$ -aryl,  $(C_3-C_8)$ -cycloalkyl,  $(C_1-C_8)$ -alkyl- $(C_3-C_8)$ -cycloalkyl or

20  $(C_3-C_8)$ -cycloalkyl- $(C_1-C_8)$ -alkyl, this optionally being linked to a polymer enlargement, and  $A$  denotes one of the following structures




25

wherein

$R$  denotes  $H$ ,  $(C_1-C_8)$ -alkyl,  $(C_6-C_{18})$ -aryl,  $(C_7-C_{19})$ -aralkyl,  $(C_1-C_8)$ -alkyl- $(C_6-C_{18})$ -aryl,  $(C_3-C_8)$ -cycloalkyl,  $(C_1-C_8)$ -alkyl- $(C_3-C_8)$ -cycloalkyl,

(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl-(C<sub>1</sub>-C<sub>8</sub>)-alkyl, or the link to a polymer enlargement, and  
 Q = O, NH, NR.

2. Ligands according to claim 1,  
 5 characterised in that  
 they correspond to the general formula (II),



wherein

10 A has the meaning given in claim 1,  
 R<sup>5</sup> to R<sup>12</sup>, independently of one another, denote  
 (C<sub>1</sub>-C<sub>8</sub>)-alkyl, HO-(C<sub>1</sub>-C<sub>8</sub>)-alkyl, (C<sub>1</sub>-C<sub>8</sub>)-alkoxy,  
 (C<sub>2</sub>-C<sub>8</sub>)-alkoxyalkyl, (C<sub>6</sub>-C<sub>18</sub>)-aryl, (C<sub>7</sub>-C<sub>19</sub>)-aralkyl,  
 (C<sub>1</sub>-C<sub>8</sub>)-alkyl-(C<sub>6</sub>-C<sub>18</sub>)-aryl, (C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl,  
 15 (C<sub>1</sub>-C<sub>8</sub>)-alkyl-(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl,  
 (C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl-(C<sub>1</sub>-C<sub>8</sub>)-alkyl,  
 or the link to a polymer enlargement.

20 3. Ligands according to claim 1 and/or 2,  
 characterised in that  
 the polymer enlargement is formed by polyacrylates,  
 polyacrylamides, polyvinylpyrrolidinones,  
 polysiloxanes, polybutadienes, polyisoprenes,  
 polyalkanes, polystyrenes, polyoxazolines or  
 polyethers or mixtures thereof.

25 4. Ligands according to claim 1, 2 and/or 3  
 characterised in that  
 they are bound to the polymer enlargement via a  
 linker selected from the group  
 a) -Si(R<sub>2</sub>)-  
 30 b) -(SiR<sub>2</sub>-O)<sub>n</sub>- n=1-10000

c)	$-(\text{CHR-CHR-O})_n-$	$n=1-10000$	
d)	$-(\text{X})_n-$	$n=1-20$	
e)	$\text{Z}-(\text{X})_n-$	$n=0-20$	
f)	$-(\text{X})_n-\text{W}$	$n=0-20$	
5	g)	$\text{Z}-(\text{X})_n-\text{W}$	$n=0-20$

wherein

R denotes H, (C<sub>1</sub>-C<sub>8</sub>)-alkyl, (C<sub>6</sub>-C<sub>18</sub>)-aryl, (C<sub>7</sub>-C<sub>19</sub>)-aralkyl, ((C<sub>1</sub>-C<sub>8</sub>)-alkyl)<sub>1-3</sub>-(C<sub>6</sub>-C<sub>18</sub>)-aryl,

X denotes  $(C_6-C_{18})$ -arylene,  $(C_1-C_8)$ -alkylene,  $(C_1-C_8)$ -alkenylene,  $((C_1-C_8)$ -alkyl $)_{1-3-}(C_6-C_{18})$ -arylene.


### (C<sub>7</sub>-C<sub>19</sub>)-aralkylene, and

*Z, W, independently of one another, denote -C(=O)O-, -C(=O)NH-, -C(=O)-, NR, O, CHR, CH<sub>2</sub>, C=S, S, PR.*

15 5. Ligands according to one or more of the above claims,  
characterised in that  
they are a homogeneously soluble catalyst.

6. Ligands according to claim 5,  
characterised in that  
the average molecular weight of the catalysts is in  
the range of 5,000 - 300,000 g/mol.

20 7. Ligands according to one or more of the above claims,  
characterised in that  
they correspond to the general formula (III) or (IV)



wherein

A and Q have the meaning in claim 1

$$R' = H \text{ or } R$$

R, independently of one another in each case, denotes (C<sub>1</sub>-C<sub>8</sub>)-alkyl, HO-(C<sub>1</sub>-C<sub>8</sub>)-alkyl, (C<sub>1</sub>-C<sub>8</sub>)-alkoxyalkyl

(C<sub>6</sub>-C<sub>18</sub>)-aryl, (C<sub>7</sub>-C<sub>19</sub>)-aralkyl,  
(C<sub>1</sub>-C<sub>8</sub>)-alkyl-(C<sub>6</sub>-C<sub>18</sub>)-aryl, (C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl,  
(C<sub>1</sub>-C<sub>8</sub>)-alkyl-(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl or  
(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl-(C<sub>1</sub>-C<sub>8</sub>)-alkyl.

5 8. Ligands according to claim 7,  
characterised in that  
R can be methyl, ethyl, propyl, iso-propyl, tert.-  
butyl or phenyl.

9. Ligands according to one or more of the above claims,  
10 characterised in that  
Q is oxygen or NR', wherein R' can be (C<sub>1</sub>-C<sub>8</sub>)-alkyl,  
(C<sub>6</sub>-C<sub>18</sub>)-aryl or benzyl.

10. Ligands according to one or more of the above claims,  
characterised in that

15 Q is oxygen or NR', wherein R' can be methyl, ethyl,  
propyl, iso-propyl, tert.-butyl, phenyl, naphthyl,  
fluorenyl or benzyl.

11. Ligands according to one or more of the above claims,  
characterised in that

20 the compounds of formulae (I) to (IV) possess an  
enantiomer enrichment of >90 %, preferably > 98%.

12. Complex containing the ligands according to claim  
1 - 11 with at least one transition metal.

25 13. Complex containing the ligands according to claim  
1 - 11 with palladium, platinum, rhodium, ruthenium,  
osmium, iridium, cobalt, nickel or copper.

14. Process for the production of the ligands according  
to claims 1 - 11,  
characterised in that

30 the corresponding phosphines are obtained by reacting  
LiP(SiMe<sub>3</sub>)<sub>2</sub> with appropriate co-reactants provided

with nucleofuge leaving groups in the presence of an organometallic base.

15. Process for the production of the ligands according to claims 1 - 11,

5 characterised in that the corresponding trimethylsilylphosphines of claim 14 are reacted with the corresponding dihalogen derivative of the structures of group A according to claim 1, the halogen atoms in each case being 10 positioned on the free valencies of the structures shown in group A in claim 1.

16. Use of a complex compound according to claim 12 or 13 as catalyst for asymmetric reactions.

17. Use of a complex compound according to claim 12 or 13

15 as catalyst for asymmetric hydrogenation, hydroformylation, rearrangement, allylic alkylation, cyclopropanation, hydrosilylation, hydride transfer reactions, hydroborations, hydrocyanations, hydrocarboxylations, aldol reactions or Heck 20 reaction.

18. Use of a complex compound according to claim 12 or 13 as catalyst for asymmetric hydrogenation and/or hydroformylation.

19. Use according to claim 18,

25 characterised in that an E/Z mixture of prochiral, N-acylated  $\beta$ -aminoacrylic acids or derivatives thereof is hydrogenated.

20. Use according to one or more of claims 17 - 19,

30 characterised in that work is performed by hydrogenation with hydrogen gas or by transfer hydrogenation.

21. Use according to claim 20, in so far as it relates to hydrogenation with hydrogen gas, characterised in that hydrogenation is performed under 0.1 to 10 bar, 5 preferably 0.5 to 5 bar, hydrogen pressure.
22. Use according to claim 21, characterised in that work is performed at temperatures of -20°C to 100°C, preferably 0°C to 50°C.
- 10 23. Use according to one or more of the above claims 16 - 22, characterised in that the substrate/catalyst ratio is selected between 10000:1 and 10:1, preferably 1000:1 and 50:1.
- 15 24. Use according to one or more of the above claims 16 - 23, characterised in that the catalysis is performed in a membrane reactor.

Fig 1:





Fig. 2:



**INTERNATIONAL SEARCH REPORT**

International Application No.  
PCT/EP 03/02162

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC 7 C07F9/50 C07F9/6568 C07F9/655 C07F9/6509 C07F9/6506 C07F15/00 B01J31/24 C07B53/00 C07C45/00 C07C231/18 //C07M7:00					
According to International Patent Classification (IPC) or to both national classification and IPC					
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07F B01J C07B C07C					
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched					
Electronic data base consulted during the International search (name of data base and, where practical, search terms used) <b>CHEM ABS Data</b>					
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>					
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.			
X	KINTING, ANNEGRET ET AL: "Asymmetric hydrogenation catalyzed by rhodium complexes of 2,3-bis(dimethylphosphino) maleic anhydride and 2,3- bis (dimethylphosphino)-N-phenylmaleimide" JOURNAL OF ORGANOMETALLIC CHEMISTRY (1986), 302(2), 259-64 , XP002244123 the whole document	1-24			
A	US 5 171 892 A (MARK J. BURK) 15 December 1992 (1992-12-15) the whole document	1-24 -/-			
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.		<input checked="" type="checkbox"/> Patent family members are listed in annex.			
* Special categories of cited documents : *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the International filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the International filing date but later than the priority date claimed					
*T* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *V* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art *D* document member of the same patent family					
Date of the actual completion of the International search		Date of mailing of the International search report			
13 June 2003		27/06/2003			
Name and mailing address of the ISA European Patent Office, P.B. 5018 Patentlaan 2 NL - 2280 HV Hoofddorp Tel: (+31-70) 340-2040, Tx: 31 651 epo nl, Fax: (+31-70) 340-3016			Authorized officer  <b>Beslier, L</b>		

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 03/02162

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation or document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	BECHER, HERMANN, J. ET AL: "Diphenylphosphinoderivate von Malein- und Fumarsäureestern: Darstellung, Eigen-schaften, Kristall- und Molekülstrukturen" MONATSHEFTE FUER CHEMIE (1978), 109(5), 1023-36 XP002244124 the whole document	1
A	BERGLUND, MATS ET AL: "Chelating phosphines on silica gel. I. Carbonyl complexes as a means to probe chelating ligand sites" JOURNAL OF ORGANOMETALLIC CHEMISTRY (1983), 258(2), 195-204 XP002244125 the whole document	1
A	AVEY, ALFRED ET AL.: "A new water-soluble phosphine for use in aqueous organometallic systems. Products from the reactions of 2,3-bis(diphenylphosphino) maleic anhydride with water and oxygen" INORGANIC CHEMISTRY, vol. 32, no. 2, 1993, pages 233-236, XP001157596 AMERICAN CHEMICAL SOCIETY, EASTON., US ISSN: 0020-1669 the whole document	1
A	FENSKE, DIETER ET AL.: "Darstellung und Eigenschaften von Derivaten des 2,3-Bis (diphenylphosphino)maleinsäure-anhydrids als Beitrag zum Problem der Farbigkeit, Konjugationsbeeinflussung und Komplexbildung dieser Stoffklasse" CHEMISCHE BERICHTE, vol. 108, no. 6, 1075, pages 2115-2123, XP002244186 VERLAG CHEMIE GMBH. WEINHEIM., DE ISSN: 0009-2940 the whole document	1
A	FENSKE, DIETER ET AL.: "2,3-Bis(diphenyl-phosphino)maleinsäureanhydrid und Diphenylphosphinoderivate des Cyclobuten-dions als Liganden in Metallcarbonylen" CHEMISCHE BERICHTE, vol. 107, no. 1, 1074, pages 117-122, XP002244187 VERLAG CHEMIE GMBH. WEINHEIM., DE ISSN: 0009-2940 the whole document	1

-/-

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 03/02162

## C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>HOLZ, JENS ET AL: "Synthesis of a New Chiral Bisphospholane Ligand for the Rh(I)-Catalyzed Enantioselective Hydrogenation of Isomeric beta-Acylamido Acrylates"  JOURNAL OF ORGANIC CHEMISTRY (2003),  68(5), 1701-1707  - 12 February 2003 (2003-02-12)  XP002244188  (GIVEN PUBLICATION DATE IS FOR PUBLICATION ON WEB)  the whole document</p>	1-24
E	<p>WO 03 031456 A (SOLVIAS AG)  17 April 2003 (2003-04-17)  claims 6,10-13</p>	1,2,7, 11,16,17

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/EP 03/02162

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
US 5171892	A	15-12-1992	AT	153667 T		15-06-1997
			DE	69220061 D1		03-07-1997
			DE	69220061 T2		11-09-1997
			EP	0592552 A1		20-04-1994
			ES	2103953 T3		01-10-1997
			HK	1001060 A1		22-05-1998
			JP	6508848 T		06-10-1994
			WO	9301199 A1		21-01-1993
			US	5386061 A		31-01-1995
			US	5565593 A		15-10-1996
			US	5559267 A		24-09-1996
			US	5596114 A		21-01-1997
			US	5532395 A		02-07-1996
			US	5329015 A		12-07-1994
WO 03031456	A	17-04-2003	WO	03031456 A2		17-04-2003